Cell penetrating peptide conjugated bioreducible polymer for siRNA delivery (2011)
PCM (primary cardiomyocyte-specific peptide) conjugated polymer
Sequence: C-WLSEAGPVTVRALRGTGSW
| Experiment Id | EXP001859 |
|---|---|
| Paper | Cell penetrating peptide conjugated bioreducible polymer for siRNA delivery |
| Peptide | PCM (primary cardiomyocyte-specific peptide) conjugated polymer |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | medium |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Polymer carrier; used as polyplex at weight ratio (polymer:siRNA) = 20 (key apoptosis/knockdown assays). |
| Rna Concentration | 50 nM siRNA (key hypoxia apoptosis assays); SHP-1 screening also at 25–100 nM. |
| Mixing Ratio | Weight ratio (polymer:siRNA) = 20 (apoptosis assays); peptide-modified polymer mixed 1:1 with unmodified CD prior to complexation. |
| Formulation Format | Peptide-conjugated bioreducible polymer/siRNA polyplex |
| Formulation Components | PCM-CD (peptide-conjugated poly(CBA-DAH) (cystamine bisacrylamide–diaminohexane bioreducible polymer)) + siRNA | Peptides (PCM and/or Tat) conjugated to poly(CBA-DAH) via SM(PEG)2; peptide-modified polymers mixed 1:1 with unmodified CD to form effective polyplexes. |
| Size Nm | 181.46 |
| Zeta Mv | 18.50 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | H9C2 rat cardiomyocytes (hypoxia-mimic CoCl2 + serum deprivation for apoptosis model) |
| Animal Model | |
| Administration Route | |
| Output Type | In vitro functional RNA effect: gene silencing + anti-apoptotic phenotype |
| Output Value | SHP-1 mRNA knockdown (qRT-PCR) and reduced apoptosis under hypoxia (Annexin V/PI; increased MTT viability; reduced LDH). |
| Output Units | |
| Output Notes | SHP-1 siRNA no.2 gave strongest knockdown; PCM+Tat polyplex gave strongest suppression and anti-apoptotic effect. |
| Toxicity Notes | MTT/LDH indicate improved viability and reduced cytotoxicity under hypoxia with SHP-1 or Fas siRNA polyplexes vs controls. |
| Curation Notes |